Psilocybin for depression and anxiety associated with life-threatening illnesses.
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 2016-11-30
- Source
- Europe PMC
- PubMed
- 27909171
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.Journal of Affective Disorders · 2018-03-31Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-06-03The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography StudyClinicalTrials.gov · 2024-04-18Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeJournal of Affective Disorders · 2023-02-02Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a WorkshopNational Academies Press (US), Washington (DC) · 2022-08-31CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-12Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysisJournal of Affective Disorders · 2026-03-21Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trialJournal of Affective Disorders · 2026-02-15